Use of (64)Cu-labeled fibronectin domain with EGFR-overexpressing tumor xenograft: molecular imaging.

PURPOSE To assess the ability of an engineered epidermal growth factor receptor (EGFR)-binding fibronectin domain to serve as a positron emission tomographic (PET) probe for molecular imaging of EGFR in a xenograft mouse model. MATERIALS AND METHODS An EGFR-binding fibronectin domain (fibronectin abbreviated to Fn when bound) was site-specifically labeled with copper 64 ((64)Cu) (8 MBq/nmol). Copper 64-Fn binding was tested in cell cultures with varying EGFR expression. Stability in human and mouse serum was measured in vitro. Animal experiments were approved by the Stanford University Institutional Animal Care and Use Committee. Copper 64-Fn (approximately 2 MBq) was used for PET in mice (n = 5) bearing EGFR-overexpressing xenografted tumors (approximately 5-10 mm in diameter). Results of tomography were compared with those of ex vivo gamma counting of dissected tissues. Statistical analysis was performed with t tests and adjustment for multiple comparisons. RESULTS Copper 64-Fn exhibited EGFR-dependent binding to multiple cell lines in culture. The tracer was stable for 24 hours in human and mouse serum at 37°C. The tracer exhibited good tumor localization (3.4% injected dose [ID]/g ± 1.0 [standard deviation] at 1 hour), retention (2.7% ID/g ± 0.6 at 24 hours), and specificity (8.6 ± 3.0 tumor-to-muscle ratio, 8.9 ± 4.7 tumor-to-blood ratio at 1 hour). Specific targeting was verified with low localization to low-expressing MDA-MB-435 tumors (0.7% ID/g ± 0.8 at 1 hour, P = .018); specificity was further demonstrated, as a nonbinding control fibronectin had low localization to EGFR-overexpressing xenografts (0.8% ID/g ± 0.2 at 1 hour, P = .013). CONCLUSION The stability, low background, and target-specific tumor uptake and retention of the engineered fibronectin domain make it a promising EGFR molecular imaging agent. More broadly, it validates the fibronectin domain as a potential scaffold for a generation of various molecular imaging agents.

[1]  S. Ståhl,et al.  Affibody Molecules for Epidermal Growth Factor Receptor Targeting In Vivo: Aspects of Dimerization and Labeling Chemistry , 2009, Journal of Nuclear Medicine.

[2]  Zhen Cheng,et al.  Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein. , 2010, Bioconjugate chemistry.

[3]  Jinming Yu,et al.  Assessment of 11C‐labeled‐4‐N‐(3‐bromoanilino)‐6, 7‐dimethoxyquinazoline as a positron emission tomography agent to monitor epidermal growth factor receptor expression , 2007, Cancer science.

[4]  Matti Anniko,et al.  Blocking EGFR in the liver improves the tumor-to-liver uptake ratio of radiolabeled EGF , 2010, Tumor Biology.

[5]  Kazunori Kawamura,et al.  [11C]Gefitinib ([11C]Iressa): Radiosynthesis, In Vitro Uptake, and In Vivo Imaging of Intact Murine Fibrosarcoma , 2010, Molecular Imaging and Biology.

[6]  Quynh-Thu Le,et al.  Cetuximab-Based Immunotherapy and Radioimmunotherapy of Head and Neck Squamous Cell Carcinoma , 2010, Clinical Cancer Research.

[7]  Wendy S. Becker,et al.  Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. , 1995, Cancer research.

[8]  Adam P. Silverman,et al.  Evaluation of a 64Cu-Labeled Cystine-Knot Peptide Based on Agouti-Related Protein for PET of Tumors Expressing αvβ3 Integrin , 2010, Journal of Nuclear Medicine.

[9]  Vladimir Tolmachev,et al.  111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  A. Koide,et al.  Monobodies: antibody mimics based on the scaffold of the fibronectin type III domain. , 2007, Methods in molecular biology.

[11]  A. Haese*,et al.  Clinical Significance of Epidermal Growth Factor Receptor Protein Overexpression and Gene Copy Number Gains in Prostate Cancer , 2007, Clinical Cancer Research.

[12]  S. Gambhir,et al.  Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects. , 2009, Cancer research.

[13]  R. Schibli,et al.  Influence of the molecular charge on the biodistribution of bombesin analogues labeled with the [99mTc(CO)3]-core. , 2008, Bioconjugate chemistry.

[14]  Q. Le,et al.  PET of EGFR Antibody Distribution in Head and Neck Squamous Cell Carcinoma Models , 2009, Journal of Nuclear Medicine.

[15]  Vladimir Tolmachev,et al.  Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-ZEGFR:2377 Affibody molecule: aspect of the injected tracer amount , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  Sanjiv Sam Gambhir,et al.  AMIDE: a free software tool for multimodality medical image analysis. , 2003, Molecular imaging.

[17]  A. Santoro,et al.  Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer , 2004, British Journal of Cancer.

[18]  J. Carlsson,et al.  In vivo and in vitro uptake of 111In, delivered with the affibody molecule (ZEGFR:955)2, in EGFR expressing tumour cells. , 2008, Oncology reports.

[19]  S. Gambhir,et al.  Small-Animal PET Imaging of Human Epidermal Growth Factor Receptor Type 2 Expression with Site-Specific 18F-Labeled Protein Scaffold Molecules , 2008, Journal of Nuclear Medicine.

[20]  D. A. Capretto,et al.  Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. , 2008, Cancer biotherapy & radiopharmaceuticals.

[21]  J. Cassady,et al.  Clinical radiation nephropathy. , 1995, International journal of radiation oncology, biology, physics.

[22]  C. Vanhove,et al.  SPECT Imaging with 99mTc-Labeled EGFR-Specific Nanobody for In Vivo Monitoring of EGFR Expression , 2008, Molecular Imaging and Biology.

[23]  Christian Vanhove,et al.  Comparison of the Biodistribution and Tumor Targeting of Two 99mTc-Labeled Anti-EGFR Nanobodies in Mice, Using Pinhole SPECT/Micro-CT , 2008, Journal of Nuclear Medicine.

[24]  Sanjiv S Gambhir,et al.  124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  M. Walter,et al.  Influence of different spacers on the biological profile of a DOTA-somatostatin analogue. , 2007, Bioconjugate chemistry.

[26]  S. Stone-Elander,et al.  On the Selection of a Tracer for PET Imaging of HER2-Expressing Tumors: Direct Comparison of a 124I-Labeled Affibody Molecule and Trastuzumab in a Murine Xenograft Model , 2009, Journal of Nuclear Medicine.

[27]  E. Shpall,et al.  Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Orditura,et al.  Epidermal Growth Factor Receptor (EGFR) Expression is Associated With a Worse Prognosis in Gastric Cancer Patients Undergoing Curative Surgery , 2007, World Journal of Surgery.

[29]  J. Feldwisch,et al.  Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules. , 2008, Bioconjugate chemistry.

[30]  Jacek Capala,et al.  Changes in HER2 Expression in Breast Cancer Xenografts After Therapy Can Be Quantified Using PET and 18F-Labeled Affibody Molecules , 2009, Journal of Nuclear Medicine.

[31]  J. Jass,et al.  A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy , 2007, British Journal of Cancer.

[32]  Steen Jakobsen,et al.  Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. , 2009, Cancer research.

[33]  Kenji Tada,et al.  Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. , 2003, Cancer research.

[34]  Michael M. Schmidt,et al.  A modeling analysis of the effects of molecular size and binding affinity on tumor targeting , 2009, Molecular Cancer Therapeutics.

[35]  Jinha M. Park,et al.  64Cu-Labeled Affibody Molecules for Imaging of HER2 Expressing Tumors , 2010, Molecular Imaging and Biology.

[36]  A. Koong,et al.  Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[37]  K. Wittrup,et al.  Stability and CDR composition biases enrich binder functionality landscapes. , 2010, Journal of molecular biology.

[38]  R. Nicholson,et al.  EGFR and cancer prognosis. , 2001, European journal of cancer.

[39]  Peter S. Conti,et al.  Pegylated Arg-Gly-Asp Peptide: 64Cu Labeling and PET Imaging of Brain Tumor αvβ3-Integrin Expression , 2004 .

[40]  Andreas Plückthun,et al.  Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. , 2010, Cancer research.

[41]  R K Jain,et al.  Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.